Skip to main content
. 2013 Nov;94(5):1079–1089. doi: 10.1189/jlb.0113036

Figure 5. Cxcl13 blockade reduced salivary gland inflammation.

Figure 5.

Female NOD mice were treated with either a control (n=8) or Cxcl13-neutralizing (mAb 5378) (n=9) antibody for 12 wk beginning at 4 wk of age. Animals received 100 μg of antibody 3 times weekly. (A, B) Periductal focal lymphocytic sialadenitis (focus scores) were quantified in control and anti-CXCL13/Cxcl13 (mAb 5378)-treated animals by analysis of H&E-stained SMG tissue. Focus scores were normalized by dividing the number of scores by the average area examined in each treatment group. Representative SMG tissue from a control and an anti-CXCL13/Cxcl13-treated animal is shown (×100). Scale bar = 200 μm. (C, D) Cd19 and Cd4 expression was assessed in SMG tissue. Tissue was homogenized and relative expression quantified by qPCR. Each sample was analyzed in duplicate; normalized expression relative to actin is shown. Significance was determined with the Mann-Whitney U test; horizontal line: sample mean. *P < 0.05; N.S., not significant.